Clinical Trial

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2023 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Trial Details
NCT Number NCT06134960
Lead Sponsor Peking University
Collaborators: KAEDI
Conditions Gastric Cancer, Pancreatic Cancer, Solid Tumor
Enrollment 12 participants
Start Date 2023-11-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2023-11-18